mirtazapine
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
1545
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
December 05, 2025
Clinical outcomes in patients with multiple myeloma and antidepressant use: A retrospective cohort study
(ASH 2025)
- "Adult patients with multiple myeloma since 2010 and prescribed antidepressants (sertraline, escitalopram, citalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, trazodone, mirtazapine, or bupropion) were identified using ICD-10 diagnostic and RxNorm codes. While some associations were modest in magnitude, the consistent pattern of increased risk suggests that pre-existing depression and its treatment may identify a more vulnerable subgroup of multiple myeloma patients. Further prospective studies are needed to clarify underlying mechanisms and to evaluate the potential impact of early psychiatric intervention."
Clinical data • Retrospective data • Chronic Kidney Disease • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Major Depressive Disorder • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Renal Disease
December 05, 2025
Antidepressant agent use and risk of bleeding in patients with cancer: Results from the vienna CAT-bled study
(ASH 2025)
- "Antidepressants were used in 218 patients (18.8%) at inclusion, with selective-serotonin re-uptake inhibitors (SSRIs) in 91 (7.8%), serotonin antagonist-re-uptake inhibitors (SARIs) in 75 (6.5%), other agents (mirtazapine, amitriptyline or bupropion) in 68 (5.9%), and serotonin-noradrenaline re-uptake inhibitors (SNRIs) in 13 (1.1%) patients. Among different types of antidepressants, the highest bleeding-risk was observed among SSRI users. Concomitant use of antidepressants and antiplatelet agents was associated with a particularly high bleeding risk, warranting further investigations."
Clinical • Gastrointestinal Disorder • Oncology • Thrombosis
December 08, 2025
Cross-linked Chitosan-Based Shell with Mirtazapine Lipid Polymer Hybrid Core as Integrated Spray-Dried Bionanocomposites for Boosted Brain-Directed Oral Delivery.
(PubMed, Mol Neurobiol)
- "The superior antidepressant efficacy of SD/TPP:CS-LPHo, especially when administered every 3 days, was also accentuated in terms of considerable amelioration of behavioral response, decreased levels of brain biomarkers (brain-derived neurotrophic factor and serotonin), and histopathological findings. In conclusion, promising brain-directed oral delivery for MIR with improved bioavailability and therapeutic efficacy can be made possible by this tactic."
Journal • CNS Disorders • Depression • Psychiatry • BDNF
December 06, 2025
Adjustment for dispensed doses does not explain higher antidepressant concentrations in post-mortem toxicology.
(PubMed, Br J Clin Pharmacol)
- "Dose adjustment generally did not improve the separation of poisoning vs non-poisoning suicides, indicating that post-mortem concentrations may not have clear dose-concentration relationships."
Journal
December 05, 2025
The impact of antidepressant use on antibiotic treatment outcomes in urinary tract infections and pneumonia: A population-based cohort study.
(PubMed, Psychiatry Clin Neurosci)
- "Antidepressants are associated with a modest rise in UTI treatment failure risk, possibly due to antibiotic resistance or other mechanisms. Despite this, their essential role in mental health management outweighs the small risk, emphasizing the need for judicious use, particularly in females and older adults. Further research is warranted to clarify underlying mechanisms."
Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases
December 05, 2025
Mirtazapine and olanzapine for cancer-related psychological distress in advanced oral cancer: efficacy and safety prospective study.
(PubMed, BMJ Support Palliat Care)
- "Both mirtazapine and olanzapine effectively reduced anxiety and depression, with mirtazapine showing greater efficacy. Mirtazapine may be preferred, though olanzapine remains a viable alternative."
Journal • CNS Disorders • Depression • Head and Neck Cancer • Mood Disorders • Oncology • Oral Cancer • Palliative care • Psychiatry • Solid Tumor
December 04, 2025
Hyperfiltration and Metabolism Before and After a Low-Calorie, Pre-Gastric Bypass Surgery Diet: Significance for Concentrations of Hydrophilic and Lipophilic Drugs.
(PubMed, Basic Clin Pharmacol Toxicol)
- "The greater the individual weight loss, the greater the concentration increase in hydrophilic drugs that undergo glomerular filtration, for example, pregabalin and gabapentin, suggesting that this reflects decreased glomerular hyperfiltration. By contrast, for highly lipophilic drugs, for example, mirtazapine and sertraline, the greater the individual creatinine and cystatin C loss, the greater the decrease in drug concentration, interpreted as increased drug metabolism based on decreased liver inflammation and steatosis. Venlafaxine/O-desmethylvenlafaxine displayed a complicated pattern suggesting the involvement of both glomerular filtration and metabolism. Serum concentrations of modestly lipophilic drugs, for example, duloxetine and (es)citalopram, were not significantly affected by the diet. In conclusion, hydrophilicity- and lipophilicity-related changes in drug concentrations over the diet period covary with markers of changes in hyperfiltration and metabolism,..."
Journal • Genetic Disorders • Inflammation • CST3
December 04, 2025
Doxepin and Mirtazapine Use in Children and Adolescents With Symptoms of Insomnia - A Single-Center Retrospective Review.
(PubMed, Pediatr Neurol)
- "We found both doxepin and mirtazapine as effective and tolerable treatments options in improving subjective sleep onset and maintenance issues in children with insomnia."
Journal • Retrospective data • CNS Disorders • Insomnia • Pediatrics • Sleep Disorder
November 28, 2025
Necl1 deficiency induces noradrenergic dysfunction and depressive-like states in rodents: A cross-species model validated by pharmacological intervention.
(PubMed, J Affect Disord)
- "Our study establishes Necl1 as a synaptic-noradrenergic integrator that gates emotional processing via region-specific circuits. The Necl1 knockout rat serves as a stable genetic model of depression, while the knockout mouse presents a valuable model for studying anxiety-related mechanisms, together providing a cross-species platform for investigating emotional regulation."
Journal • Preclinical • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry
November 26, 2025
Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis.
(PubMed, Transl Psychiatry)
- "Commonly used antidepressants have different gastrointestinal effects. Duloxetine, levomilnacipran, and vilazodone carry a higher risk of inducing nausea and vomiting, whereas trazodone, amitriptyline, agomelatine, and mirtazapine tend to be better tolerated. Amitriptyline, clomipramine, and reboxetine are more prone to induce constipation. Diarrhoea is more commonly associated with vilazodone, fluvoxamine, and sertraline. Amitriptyline, reboxetine, and duloxetine are more likely to cause anorexia. Amitriptyline, reboxetine, and trazodone are related to causing dry mouth. Compared with the placebo, amitriptyline, fluoxetine, and paroxetine were associated with a greater incidence of dyspepsia."
Journal • Retrospective data • Review • Anorexia • CNS Disorders • Constipation • Depression • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry • Xerostomia
November 22, 2025
The use of antihistamine and antihistamine-like drugs for cancer-related pain: a narrative review.
(PubMed, Support Care Cancer)
- "Analysis of these studies demonstrated meaningful evidence that antihistamine and antihistamine-like drugs may offer some benefit for treating cancer-related pain."
Journal • Review • Mucositis • Oncology • Pain • Peripheral Neuropathic Pain • Stomatitis
November 19, 2025
Real-world analysis of pharmacological treatments to prevent relapse after electroconvulsive therapy for major depressive disorder: A nationwide cohort study.
(PubMed, Transl Psychiatry)
- "The most common psychiatric drugs dispensed after ECT were antipsychotics (39.7%), mirtazapine (38.0%), and selective serotonin reuptake inhibitors (SSRI) (35.9%)...Antipsychotics were associated with a greater risk of relapse (aHR 1.17, 95% CI 1.05-1.31, p = 0.006). For other pharmacological treatments there were no associations with risk of relapse."
Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
November 11, 2025
A Novel Simple First-Derivative Synchronous Spectrofluorimetric Approach for Dual Estimation of Duloxetine and Mirtazapine in Dosage Forms and Biological Human Plasma.
(PubMed, Luminescence)
- "ICH criteria were used to validate the adopted procedure. The method's sustainability is evaluated by applying different tools, namely, Analytical Green Star Area (AGSA), Multi-Color Assessment (MA) Tool, analytical eco-scale, the Analytical Greenness Calculator (AGREE), Green Analytical Procedure Index (GAPI) and Blue Applicability Grade Index (BAGI)."
Journal • CNS Disorders • Depression • Psychiatry
November 13, 2025
A Case of Cerebellar-Onset Progressive Multifocal Leukoencephalopathy (PML) Associated with Hepatitis B-related Liver Cirrhosis.
(PubMed, Intern Med)
- "Treatment with mefloquine and mirtazapine resulted in viral clearance from the cerebrospinal fluid (CSF) and clinical stabilization. This case highlights that crescent-shaped cerebellar lesions should raise suspicion of PML, even in patients without severe immunodeficiency."
Journal • Ataxia • CNS Disorders • Fibrosis • Gastroenterology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Movement Disorders • Rare Diseases
October 18, 2025
Hyponatremia Associated with Sjogren Disease
(KIDNEY WEEK 2025)
- "She was taking 50 mcg of levothyroxine and 7.5 mg of mirtazapine daily...Sodium was corrected with 3% saline and DDAVP clamp protocol...Patient will continue to be investigated and treated for hyponatremia and hypokalemia. This case serves as a reminder to be aware of hyponatremia having a rare association with SD."
Cardiovascular • CNS Disorders • Dry Eye Disease • Endocrine Disorders • Fibromyalgia • Heart Failure • Hypertension • Immunology • Infectious Disease • Insomnia • Musculoskeletal Diseases • Musculoskeletal Pain • Obstructive Sleep Apnea • Ophthalmology • Orthopedics • Respiratory Diseases • Rheumatology • Sjogren's Syndrome • Sleep Disorder
October 18, 2025
Cerebral Salt-Wasting Syndrome Masquerading as Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Patient with Subdural Hemorrhage
(KIDNEY WEEK 2025)
- "His home medications included insulin, losartan, mirtazapine, and doxazosin...To prevent worsening hyponatremia with ongoing natriuresis, he was started on sodium tablets, urea tablets, and fludrocortisone...The common etiologies of CSWS include central nervous system pathologies, the most common being aneurysmal subarachnoid hemorrhage. This case underscores the importance of monitoring volume status and electrolytes in neurologically injured patients with hyponatremia."
Clinical • Benign Prostatic Hyperplasia • Cachexia • Cardiovascular • CNS Disorders • Diabetes • Heart Failure • Hematological Disorders • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Subarachnoid Hemorrhage
November 11, 2025
The Use of Multiple Sleep Medications Is Highly Prevalent
(ISPOR-EU 2025)
- "Melatonin and mirtazapine comprised the most common two-drug combination, with quetiapine added for the most common three-drug combination. Sleep medication use is highly prevalent, especially among older adults. Sleep medication use is highly prevalent, especially among older adults. Special attention should be paid when multiple sleep medications are used concurrently, as this increases the risk of adverse outcomes such as cognitive decline, falls, and drug interactions. These may lead to increased healthcare use and costs, including emergency visits and hospitalizations."
CNS Disorders • Insomnia • Sleep Disorder
November 10, 2025
Concomitant Psychotropic Medication is Associated with Reduced Outcomes of Trauma-Focused Psychotherapy for Post-Traumatic Stress Disorder.
(PubMed, Psychother Psychosom)
- "Several psychotropic co-medications were associated with reduced outcomes of evidence-based trauma-focused psychotherapy for PTSD. By identifying this as a potentially modifiable factor, psychotherapy outcomes may be optimized. Trials are warranted to evaluate whether tapering or substituting these agents improves outcomes."
Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
November 08, 2025
Sexual Dysfunction in Male Patients After Initiating Treatment with Antidepressants.
(PubMed, Drug Saf)
- "The risk of developing sexual dysfunction varies across antidepressant treatment. Healthcare providers should discuss the potential for sexual side effects, particularly when multiple treatment options are available."
Journal • CNS Disorders • Depression • Psychiatry • Sexual Disorders
November 05, 2025
The cost of drug repurposing: parallel economic evaluation of mirtazapine for severe breathlessness in the multinational BETTER-B trial.
(PubMed, BMC Health Serv Res)
- No abstract available
HEOR • Journal
November 04, 2025
Regional brain morphology and current antidepressant use: findings from 32 international cohorts from the ENIGMA major depressive disorder working group.
(PubMed, Mol Psychiatry)
- "Additionally, we examined the effect of AD type (SSRI, SNRI or mirtazapine) and duration of use on brain morphology...Evidence for subtle structural brain differences in temporal and limbic regions in individuals with MDD who currently use AD medication were found compared to those not currently taking AD medication. Future longitudinal studies are needed to determine the causality of these associations."
Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
October 06, 2025
The Starved Heart: Pericarditis in Extreme Anorexia Nervosa
(AHA 2025)
- "Pericarditis was treated with ibuprofen and colchicine. Psychiatric therapy included olanzapine and mirtazapine for appetite stimulation and mood support...Symptomatic pericarditis is a rare but serious cardiac complication of AN. Early diagnosis and coordinated multidisciplinary care are essential for recovery."
Anorexia • Cardiovascular • Depression • Gastrointestinal Disorder • Hypotension • Immunology • Inflammation • Major Depressive Disorder • Mental Retardation • Mood Disorders • Pulmonary Disease • Renal Disease • Respiratory Diseases • Women's Health
August 30, 2025
Rising Enzymes: The Hepatic Fallout of Refeeding Syndrome
(ACG 2025)
- "Medications included mirtazapine, paliperidone, vitamin B1/B6 and vitamin D3...Liver enzyme elevations should not deter nutritional support, as treating the underlying malnutrition remains priority. With careful monitoring and gradual refeeding, this case illustrates that liver function often improves alongside nutritional status."
Autoimmune Hepatitis • CNS Disorders • Hepatology • Immunology • Inflammation • Liver Failure • Psychiatry • Schizophrenia
August 30, 2025
Disparities in Healthcare and Utilization Between Cisgender versus Transgender and Gender Non-Conforming Patients With Irritable Bowel Syndrome
(ACG 2025)
- "Outcomes included colonic surgery, endoscopy, inpatient and emergency visits, and prescriptions for anti-diarrheal, anti-constipation, or adjunctive medicines (e.g., anti-spasmodics, mirtazapine, or tricyclics). This study identified 1,154,340 cisgender and 3,861 TGNC IBS patients... This study identified 1,154,340 cisgender and 3,861 TGNC IBS patients. After matching, each group included 3,832 patients. TGNC patients were generally younger and more likely to be male, white, or Hispanic."
Clinical • Cardiovascular • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Mental Retardation • Psychiatry
August 30, 2025
Efficacy of Mirtazapine in Patients With Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
(ACG 2025)
- "This meta-analysis included three RCTs involving 214 patients aged 18 to 70 years with functional dyspepsia (FD). Of these, 94 patients experienced weight loss following their FD diagnosis. The studies used the Rome III and IV criteria for inclusion."
Retrospective data • Review • Dyspepsia • Gastroenterology • Gastrointestinal Disorder
1 to 25
Of
1545
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62